Optimizing Metrics for the Assessment of Bioequivalence Between Topical Drug Products
- 261 Downloads
Stratum corneum tape stripping post-application of a drug product followed by analysis of the active agent in this tissue layer is an approach being seriously considered for the comparative assessment of topical bioavailability. Key issues revolve around how best to perform this experiment and interpret the data.
Using previously published results from a comparative study of three 0.025% tretinoin gel products, alternative data analysis approaches are presented that may render the technique more accessible to the evaluation of new and generic topical dosage forms.
For the tretinoin gel study, the conclusions for bioequivalence from measurements of drug levels at only one uptake and one clearance time were the same as those from the original study, which required measurements at eight different treatment times. Furthermore, comparisons of drug levels at one uptake and one clearance time discriminated differences in bioequivalence for clearance and uptake, which had previously been missed. Half-life estimates, derived from time course data of drug clearance, can be related to lag time for drug penetration through the SC.
This new data analysis demonstrates that comparative bioequivalence might be assessed more easily.
KEY WORDSdermatopharmacokinetics skin stratum corneum tape stripping topical drug bioequivalence
We acknowledge support from the FDA. No endorsement from the FDA or US government should be inferred.
- 1.V. P. Shah, G. L. Flynn, A. Yacobi, H. I. Maibach, C. Bon, N. M. Fleischer, T. J. Franz, S. A. Kaplan, J. Kawamoto, L. J. Lesko, J.-P. Marty, L. K. Pershing, H. Schaefer, J. A. Sequeira, S. P. Shrivastave, J. Wilkins, and R. L. Williams. Bioequivalence of topical dermatological dosage forms—methods of evaluation of bioequivalence. Pharm. Res. 15:167–171 (1998).PubMedCrossRefGoogle Scholar
- 2.US FDA. Guidance for Industry: topical dermatological drug product NDAs and ANDAs-in vivo bioavilability, bioequivalence, in vitro release, and associated studies. Draft Guidance, June 1998, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), 1998.Google Scholar
- 4.L. K. Pershing. Final Report to Food and Drug Administration (FDA): Dermatopharmacokinetic Bioequivalence Study on Three Tretinoin Gel, 0.025% Products, University of Utah, Salt Lake City, 2000.Google Scholar
- 5.US FDA. Guidance for industry on special protocol assessment; availability. Fed. Reg. 67:35122 (2002).Google Scholar
- 6.A. L. Bunge, B. N’Dri-Stempfer, W. C. Navidi, and R. H. Guy. Dermatopharmacokinetics: Improvement of Methodology for Assessing Bioequivalence of Topical Dermatological Drug Products, Revised Final Report, Award No. D3921303, Submitted to Department of Health and Human Services, Food and Drug Administration, Colorado School of Mines, Golden, CO, September 2, 2006.Google Scholar
- 7.A. L. Bunge, B. N’Dri-Stempfer, W. C. Navidi, and R. H. Guy. Therapeutic Equivalence of Topical Products, Final Report, Award No. 223-04-3004, Submitted to Department of Health and Human Services, Food and Drug Administration, Colorado School of Mines, Golden, CO, January 30, 2007.Google Scholar
- 8.L. K. Pershing. Bioequivalence Assessment of three 0.025% tretinoin gel products: Dermatopharmacokinetic vs. Clinical Trial Methods. Advisory Committee for Pharmaceutical Sciences Meeting, Center for Drug Evaluation and Research (CDER), Food and Drug Administration (FDA), Rockville, MD, 2001.Google Scholar
- 9.T. J. Franz. Study #1, Avita Gel 0.025% vs Retin-A Gel 0.025%, Advisory Committee for Pharmaceutical Sciences Meeting, Center for Drug Evaluation and Research (CDER), Food and Drug Administration (FDA), Rockville, MD, 2001.Google Scholar
- 10.D. P. Conner. Differences in DPK Methods. Advisory Committee for Pharmaceutical Sciences Meeting, Center for Drug Evaluation and Research (CDER), Food and Drug Administration (FDA), Rockville, MD, 2001. http://www.fda.gov/ohrms/dockets/ac/01/slides/3804s2_05_conner/index.htm, pp 71–75 in transcript.
- 17.M. S. Roberts, and K. A. Walters. The relationship between structure and barrier function of skin. In M. S. Roberts, and K. A. Walters (eds.), Dermal Absorption and Toxicity Assessment, Vol 91., Drugs and the Pharmaceutical Sciences, Marcel Dekker, New York, 1998, pp. 1–42.Google Scholar
- 19.E. Kreyszig. Advanced Engineering Mathematics. 8th Edition, Wiley, New York, NY, 1999.Google Scholar
- 21.US FDA. Avita Gel (Tretinoin Gel), NDA Application No.: 20-400. http://www.fda.gov/cder/foi/nda/98/20400.htm, 1998.
- 22.US FDA. Approved drug products with therapeutic equivalence evaluations (Electronic Orange Book), US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmaceutical Science, Office of Generic Drugs. http://www.fda.gov/cder/orange/obannual.pdf, 2007.